Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMEA NASDAQ:DYAI NASDAQ:ONCY NASDAQ:VRCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.64+7.6%$1.53$0.87▼$3.08$118.21M-0.321.42 million shs1.29 million shsDYAIDyadic International$0.77+0.1%$0.82$0.65▼$1.35$28.10M1.1862,155 shs1,707 shsONCYOncolytics Biotech$0.94+2.2%$1.00$0.33▼$1.51$107.77M1.021.33 million shs709,204 shsVRCAVerrica Pharmaceuticals$8.07+12.8%$5.75$3.28▼$9.82$140.19M1.54125,677 shs214,834 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion+10.95%-0.65%-1.30%+39.45%-24.00%DYAIDyadic International-2.52%-4.94%-13.47%-9.10%-34.74%ONCYOncolytics Biotech+5.16%+1.62%-4.72%+1.67%+67.89%VRCAVerrica Pharmaceuticals+14.19%+9.65%+30.90%+0.28%+60.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.64+7.6%$1.53$0.87▼$3.08$118.21M-0.321.42 million shs1.29 million shsDYAIDyadic International$0.77+0.1%$0.82$0.65▼$1.35$28.10M1.1862,155 shs1,707 shsONCYOncolytics Biotech$0.94+2.2%$1.00$0.33▼$1.51$107.77M1.021.33 million shs709,204 shsVRCAVerrica Pharmaceuticals$8.07+12.8%$5.75$3.28▼$9.82$140.19M1.54125,677 shs214,834 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion+10.95%-0.65%-1.30%+39.45%-24.00%DYAIDyadic International-2.52%-4.94%-13.47%-9.10%-34.74%ONCYOncolytics Biotech+5.16%+1.62%-4.72%+1.67%+67.89%VRCAVerrica Pharmaceuticals+14.19%+9.65%+30.90%+0.28%+60.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMEABiomea Fusion 2.89Moderate Buy$8.29406.77% UpsideDYAIDyadic International 2.33Hold$3.00289.11% UpsideONCYOncolytics Biotech 2.60Moderate Buy$8.50809.09% UpsideVRCAVerrica Pharmaceuticals 1.75Reduce$17.00110.55% UpsideCurrent Analyst Ratings BreakdownLatest DYAI, VRCA, ONCY, and BMEA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026BMEABiomea Fusion CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Outperform5/5/2026BMEABiomea Fusion Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$9.004/28/2026BMEABiomea Fusion D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/24/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026BMEABiomea Fusion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026BMEABiomea Fusion D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/7/2026VRCAVerrica Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/27/2026DYAIDyadic International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026BMEABiomea Fusion CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $7.003/25/2026BMEABiomea Fusion D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMEABiomea FusionN/AN/AN/AN/A$0.42 per shareN/ADYAIDyadic International$3.09M9.09N/AN/A$0.03 per share25.70ONCYOncolytics BiotechN/AN/AN/AN/A($0.04) per shareN/AVRCAVerrica Pharmaceuticals$35.58M3.90N/AN/A$1.55 per share5.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMEABiomea Fusion-$61.80M-$1.31N/AN/AN/AN/A-305.60%-128.09%5/6/2026 (Estimated)DYAIDyadic International-$7.36M-$0.25N/AN/AN/A-239.67%-695.96%-78.24%5/13/2026 (Estimated)ONCYOncolytics Biotech-$28.76M-$0.29N/AN/AN/AN/A-2,185.97%-243.94%5/13/2026 (Estimated)VRCAVerrica Pharmaceuticals-$17.89M-$1.58N/AN/AN/A-50.27%N/A-40.08%5/12/2026 (Estimated)Latest DYAI, VRCA, ONCY, and BMEA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026DYAIDyadic International-$0.04N/AN/AN/A$0.90 millionN/A5/13/2026Q1 2026ONCYOncolytics Biotech-$0.05N/AN/AN/AN/AN/A5/12/2026Q1 2026VRCAVerrica Pharmaceuticals-$0.59N/AN/AN/A$4.51 millionN/A5/6/2026Q1 2026BMEABiomea Fusion-$0.24N/AN/AN/AN/AN/A3/30/2026Q4 2025ONCYOncolytics Biotech-$0.06-$0.08-$0.02-$0.08N/AN/A3/25/2026Q4 2025DYAIDyadic International-$0.03-$0.06-$0.03-$0.06$1.34 million$0.57 million3/11/2026Q4 2025VRCAVerrica Pharmaceuticals-$0.43-$0.51-$0.08-$0.57$4.52 million$5.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBMEABiomea FusionN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMEABiomea FusionN/A5.235.23DYAIDyadic International4.082.682.68ONCYOncolytics BiotechN/A1.121.12VRCAVerrica Pharmaceuticals0.032.592.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMEABiomea Fusion96.72%DYAIDyadic International27.95%ONCYOncolytics Biotech6.82%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipBMEABiomea Fusion18.42%DYAIDyadic International29.50%ONCYOncolytics Biotech0.10%VRCAVerrica Pharmaceuticals54.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMEABiomea Fusion5072.30 million58.98 millionOptionableDYAIDyadic International736.44 million25.69 millionOptionableONCYOncolytics Biotech30116.13 million116.01 millionNot OptionableVRCAVerrica Pharmaceuticals4017.18 million7.90 millionNo DataDYAI, VRCA, ONCY, and BMEA HeadlinesRecent News About These CompaniesVerrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual MeetingMay 5 at 4:05 PM | globenewswire.comVerrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate ...May 5 at 3:50 PM | bakersfield.comBVerrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on TuesdayMay 5 at 1:06 PM | marketbeat.comVerrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026May 5 at 8:00 AM | globenewswire.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest UpdateApril 30, 2026 | marketbeat.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Rating of "Reduce" by BrokeragesApril 17, 2026 | marketbeat.comVerrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the ...April 10, 2026 | markets.businessinsider.comVerrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual MeetingApril 9, 2026 | globenewswire.comVerrica Pharmaceuticals (NASDAQ:VRCA) Cut to Strong Sell at Zacks ResearchApril 9, 2026 | marketbeat.comVerrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 6, 2026 | globenewswire.comVRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. - VRCAMarch 21, 2026 | tmcnet.comVRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law FirmMarch 20, 2026 | businesswire.comVRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCAMarch 20, 2026 | businesswire.comVerrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. - VRCAMarch 19, 2026 | tmcnet.comVerrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCAMarch 19, 2026 | businesswire.comVerrica Pharmaceuticals reports 2025 results and YCANTH sales growthMarch 16, 2026 | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR)March 12, 2026 | theglobeandmail.comVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 11, 2026 | finanznachrichten.deVerrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...March 11, 2026 | finance.yahoo.comVerrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call TranscriptMarch 11, 2026 | seekingalpha.comVerrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 11, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDYAI, VRCA, ONCY, and BMEA Company DescriptionsBiomea Fusion NASDAQ:BMEA$1.64 +0.12 (+7.57%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Dyadic International NASDAQ:DYAI$0.77 +0.00 (+0.12%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Oncolytics Biotech NASDAQ:ONCY$0.94 +0.02 (+2.19%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Verrica Pharmaceuticals NASDAQ:VRCA$8.07 +0.91 (+12.77%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage Years in the Making, AMD’s Upside Movement Has Just Begun Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Pinterest Pins a Profit Play To Its Mood Board Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
